Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4144 for Infusion · 1 trial · 1 indication
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faeces and all excreta
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating total radioactivity
Identification of greater than 80% of the radioactivity recovered in the urine and/or faeces
| Arm | Type | Description |
|---|---|---|
| Regimen A | EXPERIMENTAL | Participants in Cohort 1 will receive a single intravenous injection of \[14C\]AZD4144 Solution for Infusion |
| Regimen B | EXPERIMENTAL | Participants in Cohort 2 will receive a single oral dose of \[14C\]AZD4144 Oral Solution |
| Name | Type | Description |
|---|---|---|
| [14C]AZD4144 Solution for Infusion | DRUG | Intravenous, fasted |
| [14C]AZD4144 Oral Solution | DRUG | Oral, fasted |
Inclusion Criteria: * Healthy males aged 30 to 65 years inclusive * BMI of 18.0 to 32.0 kg/m2 inclusive * Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day) Exclusion Criteria: * History of any clinically important disease or disorder * History or presence of clin...
AZD4144 for Infusion is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with a completed trial evaluating its absorption, distribution, metabolism, and excretion. The drug is not approved and remains under investigation.
AZD4144 for Infusion is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting early-stage clinical research on this investigational small molecule.
AZD4144 for Infusion is in Phase 1 clinical development. One Phase 1 trial has been completed, involving 16 healthy participants in the United Kingdom. The drug is investigational and has not been approved for any use.
AZD4144 for Infusion has one completed clinical trial, NCT07518459, titled "A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144." This Phase 1 study enrolled 16 healthy participants aged 30 years and older in the United Kingdom.
AZD4144 for Infusion is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A single Phase 1 trial has been completed, but the drug remains under study and has not been authorized for commercial use.